We have located links that may give you full text access.
[T-Lymphoblastic Lymphoma Combined with Acute Myeloid Leukemia].
Zhongguo Shi Yan Xue Ye Xue za Zhi 2018 October
OBJECTIVE: To investigate the diagnosis and treatment of patients with T-lymphoblastic lymphoma(T-LBL)combined with acute myeloid leukemia(AML).
METHODS: The clinical features of 4 patients with T-LBL combined with AML were retrospectively analyzed, Among them the case 1 and 2 were synchronous occurrence,and case 3 and 4 were sequentially occurred. Especially for former 2 patients,the dliagnosis differentiated from the involved lymph node of AML is important.
RESULTS: The biopsies, immunohistochemical(IHC)test and T-cell receptor(TCR)gene rearrangement of the lymph node have been re-evaluated in our institulion. The diagnosis of T-LBL was confirmed. The diagnosis of AML was based on morphology,cytochemistry,immunophenotypy,karyotype and fusion gene of cells. The biphenotypic and bilineal types were found by flow cytometriy(FCM). The diagnosis of mixed acute leukemin(MAL)was confirmed. All the patients received chemotherapy,all of which died from leukemia. The survivnl duration was 2 to 5 months from the diagnosis of AML.
CONCLUSION: T-LBL combined with AML is an aggressive disease with am unfarourable prognosis, The new therapies should be designed to treat these rare cases.
METHODS: The clinical features of 4 patients with T-LBL combined with AML were retrospectively analyzed, Among them the case 1 and 2 were synchronous occurrence,and case 3 and 4 were sequentially occurred. Especially for former 2 patients,the dliagnosis differentiated from the involved lymph node of AML is important.
RESULTS: The biopsies, immunohistochemical(IHC)test and T-cell receptor(TCR)gene rearrangement of the lymph node have been re-evaluated in our institulion. The diagnosis of T-LBL was confirmed. The diagnosis of AML was based on morphology,cytochemistry,immunophenotypy,karyotype and fusion gene of cells. The biphenotypic and bilineal types were found by flow cytometriy(FCM). The diagnosis of mixed acute leukemin(MAL)was confirmed. All the patients received chemotherapy,all of which died from leukemia. The survivnl duration was 2 to 5 months from the diagnosis of AML.
CONCLUSION: T-LBL combined with AML is an aggressive disease with am unfarourable prognosis, The new therapies should be designed to treat these rare cases.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app